Source link : https://www.newshealth.biz/health-news/imcivree-label-expanded-weight-loss-with-weekly-injection-kidney-donation-chain/
The FDA expanded the indication for setmelanotide (Imcivree) to include children as young as 2 years with syndromic or monogenic obesity due to Bardet-Biedl syndrome or genetically confirmed pro-opiomelanocortin, said maker Rhythm Pharmaceuticals. Among patients with type 2 diabetic nephropathy receiving bremelanotide in the small phase IIb BREAKOUT study, 71% achieved greater than 30% reduction […]
Author : News Health
Publish date : 2024-12-24 17:30:00
Copyright for syndicated content belongs to the linked Source.